Clinical trials: Digestive Disease
Colon Cancer, Pancreatic Cancer
A Study of PHN-012 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
- Conditions
- Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
- Trial name
- NCT07127874
- Testing
- PHN-012
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 165 people
- Sponsor
- Pheon Therapeutics
B-cell Malignancies, Colorectal Cancer (CRC)
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors…
- Conditions
- B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer
- Trial name
- NCT02327078
- Testing
- Nivolumab, Epacadostat, Chemotherapy
- Where
- 24 sites in United States, United Kingdom
- Volunteers
- 307 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumor, Hepatocellular Carcinoma
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer.
- Trial name
- NCT06005740
- Testing
- TORL-4-500
- Where
- 10 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Inflammatory Bowel Disease
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
This study will be conducted to observe the difference in microbiome composition between healthy participants and inflammatory bowel disease (IBD) participants with no anti-tumor necrosis factor (anti-TNF) treatment.
- Trial name
- ETERNITY (NCT03264690)
- Where
- 3 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eisai Korea Inc.
Irritable Bowel Syndrome
DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is the most commonly identified functional gastrointestinal disorder, affecting 10-20% of the population in the Western world, seen predominantly in females and with a negative impact on quality of…
- Trial name
- NCT00220090
- Testing
- dexloxiglumide
- Where
- United Kingdom
- Sponsor
- Rottapharm
Chronic Hepatitis B
Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B
This randomized controlled trial is designed to evaluate safety, effectiveness and pharmacokinetic-pharmacodynamic (PK/PD) relationships associated with three different Nitazoxanide (NTZ) treatment regimens added to Tenofovir…
- Trial name
- NCT03905655
- Testing
- Nitazoxanide
- Where
- Singapore
- Volunteers
- 51 people
- Sponsor
- Romark Laboratories L.C.
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Liver Cancer Registry Platform
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- JADE (NCT04510740)
- Testing
- Physician's choice according to patient's needs.
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- iOMEDICO AG
Cystic Fibrosis
An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
The purpose of this study is to evaluate the effect of Vanzacaftor (VNZ) on QTcF, as well as the pharmacokinetic (PK), safety, and tolerability of VNZ in healthy participants.
- Trial name
- NCT05867147
- Testing
- Vanzacaftor, Moxifloxacin
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Gastrointestinal Stromal Tumors
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
To evaluate the antitumor activity of SU011248 in advanced, imatinib mesylate-resistant gastrointestinal stromal tumor (GIST) when administered on a continuous daily dosing schedule
- Trial name
- NCT00137449
- Testing
- SU011248
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- Pfizer
Hepatic Fibrosis
QTc Assessment in a Single-Dose Study of Hydronidone Capsules
This study was designed with three dose cohorts (A1-A3): a 90 mg cohort, a 270 mg cohort, and a 540 mg cohort. Each cohort enrolled 16 healthy Chinese participants, with 12 receiving the investigational product Hydronidone…
- Trial name
- NCT07263152
- Testing
- Hydronidone
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Mesothelioma, Pancreatic Cancer
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
This research is being conducted to determine the biodistribution of radiolabeled amatuximab in tumor and non-tumor tissues in subjects with mesothelin over expressing cancer including mesothelioma, pancreatic, ovarian or non…
- Conditions
- Mesothelioma, Pancreatic Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT01521325
- Testing
- Amatuximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Morphotek
Celiac Disease
Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal
ALV003-0812 is a study of the safety and tolerability of a study drug (ALV003) in healthy adult volunteers and in patients with well-controlled celiac disease, following a meal that contains gluten.
- Trial name
- FED (NCT00669825)
- Testing
- ALV003
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Alvine Pharmaceuticals Inc.
HCV Infection
Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
This study will collect and evaluate information on the safety and efficacy of Sovaldi-based regimens in routine clinical practice in Mexico.
- Trial name
- NCT02783976
- Testing
- Sovaldi
- Where
- 6 sites in Mexico
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Liver Cirrhosis
Using Autologous Bone Marrow Cells With Wharton Gel Exosomes to Stimulate Hepatic Cell Repair in Liver Cirrhosis
the study includes patients with liver cirrhosis irrespective of the stage excluding people with active tumor or other major health issue endangering life, the protocol includes the use of autologous bone marrow derived…
- Trial name
- bone marrow (NCT07374185)
- Testing
- Autologous Bone Marrow Aspirate Concentrate
- Where
- Iraq
- Volunteers
- 10 people
- Sponsor
- Global Stem Cell Center, Baghdad
Biliary Tract Cancer (BTC), Colorectal Cancer (CRC)
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
- Conditions
- Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC)
- Trial name
- NCT03314935
- Testing
- INCB001158, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 149 people
- Sponsor
- Incyte Corporation
Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).
- Conditions
- Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type
- Trial name
- NCT05160168
- Testing
- THE-630
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Theseus Pharmaceuticals
Neurogenic Dysphonia, Neurogenic Dysphagia
Neurogenic Dysphonia/Dysphagia Registry
The Neurogenic Dysphonia/Dysphagia Registry is designed to be purely observational (i.e. non-interventional, exploratory). Patient data collected from the registry is expected to be consistent with any information which can be…
- Trial name
- StrongVoice (NCT02493491)
- Where
- 12 sites in United States
- Volunteers
- 146 people
- Sponsor
- Merz North America, Inc.
HCV Infection
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
The purpose of this study is to assess the safety, tolerability and effectiveness of ANA598 when administered with pegylated interferon and ribavirin (Standard of Care [SOC]) compared to placebo + SOC.
- Trial name
- NCT00978497
- Testing
- ANA598, Peginterferon, Ribavirin
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.